Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime

Authors:

Abstract
Background Recent evidence suggests that among patients receiving vancomycin, receipt of concomitant piperacillin/tazobactam increases the risk of nephrotoxicity. Well controlled, adequately powered studies comparing rates of acute kidney injury (AKI) among patients receiving vancomycin + piperacillin/tazobactam (VPT) compared to similar patients receiving vancomycin + cefepime (VC) are lacking. This study compared the incidence of AKI among patients receiving combination therapy with VPT to a matched group of patients receiving VC. Methods A retrospective matched cohort study was performed. Patients were eligible if they received combination therapy with either VC or VPT for ≥ 48 hours. Patients were excluded if their baseline serum creatinine was >1.2mg/dl or they were receiving renal replacement therapy. Patients receiving VC were matched to patients receiving VPT based on severity of illness, ICU status, duration of combination therapy, vancomycin dose and number of concomitant nephrotoxins. The primary outcome was the incidence of RIFLE criteria-defined AKI. Multivariate modeling was performed using Cox proportional hazards. Results 558 patients were included. The mean age was 55.9±16.6 years. AKI rates were significantly higher in the VPT than the VC group (81/279 (29%) vs. 31/279 (11%).) In multivariate analysis, therapy with VPT was an independent predictor for AKI (HR=4.27, 95% CI 2.73-6.68). Among patients who developed AKI, the median onset was more rapid in the VPT compared to the VC group (3 vs. 5 days, p=Conclusion The VPT combination was associated with both an increased AKI risk and a more rapid onset of AKI, compared to the VC combination.

This publication has 12 references indexed in Scilit: